Abstract��OBJECTIVE To establish a high performance liquid chromatography mass spectrometry (HPLC-MS/MS) method to determine the cinacalcet concentration in plasma of dialysis patients.METHODS Fendiline hydrochloride was selected as the internal standard (IS), in the meantime, plasma samples were extracted through the solid phase extraction (SPE), and the internal standard method was used to determine the concentration of cinacalcet. The analyte was separated by Inertsil SIL-150A (2.1 mm��50 mm, 5 ��m) matched with guard column Inertsil SIL-150A (3.0 mm��50 mm,5 ��m). The cinacalcet was eluted with acetonitrile, water and formic acid (90��10��1=V��V��V) at a rate of 0.35 mL��min-1. On MS, electrospray ionization (ESI) source with positive ion mode and multiply reaction monitoring (MRM) was used. The MRM transitions of cinacalcet and the IS were 358.1��155.1 and 316.0��212.1, respectively. The concentration in dialysis patients after 25 mg dose (one piece of tablet) within 24 h was determined by using the established HPLC-MS/MS method in this paper.RESULTS A good linearity was obtained in the range of 0.1-50 ng��mL-1 of cinacalcet, and the validated accuracy and precision all were within ��15%. Long-term, freeze-thaw and autoinjector stability of cinacalcet QC samples were all in the range of 1.4%-3.9%. The matrix of cinacalcet is (104.5��3.1)%, (105.6��4.3)% and (104.0��3.1)% respectively and the matrix of IS is (106.4��3.0)%. This validated method can meet the guidance for bioanalytical method validation.CONCLUSION The HPLC-MS/MS method is sensitive and specific enough to meet the quantitative requirements for determining cinacalcet in human plasma. It is rapid, accurate and in line with the guidance for bioanalytical method validation.
̷����,ʱ�ľ�,������,���ж�,�¾�,������. Һ�����÷��ⶨ�������������ǿ�����ѪҩŨ��[J]. �й�ҩѧ��־, 2018, 53(13): 1098-1103.
TAN Xiu-yan, SHI Wen-juan, ZHANG Min-min, LI Zhong-dong, CHEN Jing, ZHONG Ming-kang(a.. Quantitative Determination of Cinacalcet in Dialysis Patients�� Plasma by a High Performance Liquid Chromatography Mass Spectrometry Method. Chinese Pharmaceutical Journal, 2018, 53(13): 1098-1103.
BOVER J, URENA P, RUIZ-GARCIA C, et al. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism[J]. Clin J Am Soc Nephrol, 2016,11(1):161-174.
[2]
BASHIR S O, OMER H A, AAMER M A, et al. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients[J]. Saudi J Kidney Dis Transpl, 2015,26(6):1135-1141.
[3]
TAN X Y, ZHANG M M, LI Z D, et al. Research progress on cinacalcet hydrochloride against hyperparathyroidism [J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2017, 37(2):185-189.
[4]
MEI C, CHEN N, DING X, et al. Efficacy and safety of cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis[J]. Hemodial Int, 2016,20(4):589-600.
[5]
BILEZIKIAN J P, BRANDI M L, EASTELL R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop[J]. J Clin Endocrinol Metab, 2014,99(10):3561-3569.
[6]
COHEN J B, GORDON C E, BALK E M, et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and Meta-analysis[J]. Transplantation, 2012,94(10):1041-1048.
[7]
PADHI D, HARRIS R Z, SALFI M, et al. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (sensipar/mimpara) [J]. Clin Pharmacokinet, 2005,44(5):509-516.
[8]
CANGEMI G, BARCO S, VERRINA E E, et al. Micromethod for quantification of cinacalcet in human plasma by liquid chromatography-tandem mass spectrometry using a stable isotope-labeled internal standard[J]. Ther Drug Monit, 2013,35(1):112-117.
[9]
YANG F, WANG H, ZHAO Q, et al. Determination of cinacalcet hydrochloride in human plasma by liquid chromatography-tandem mass spectrometry[J]. J Pharm Biomed Anal, 2012,61:237-241.
[10]
SERRA L, BRAUN S C, STARKE A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation[J]. Am J Transplant, 2008,8(4):803-810.
[11]
HARRIS R Z, PADHI D, MARBURY T C, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily[J]. Am J Kidney Dis, 2004,44(6):1070-1076.
[12]
WEI M J, LI L, ZHANG Y H, et al. Discussions on the inaccuracy problems and preventing strategies associated with the use of liquid chromatography-tandem mass spectrometry in quantitative assay of biosamples[J]. Chin Pharm J(�й�ҩѧ��־), 2015, 50 (11):925-930.
[13]
ZHANG Y, CHEN Y N, CHEN C H. Determination of 13 drugs in plasma by high performance liquid chromatography with solid phase extraction[J]. Chin Pharm J(�й�ҩѧ��־), 2010,45(21):1648-1651.
2018, Vol. 53 
